Background. Icodextrin dialysate used for peritoneal dialysis contains an iso-molar glucose polymer solution, which provides sustained ultrafiltration over long dwell times and is considered a valuable approach to reduce intraperitoneal glucose exposure. However, several side effects have been described, including abdominal pain and allergic and hypersensitivity reactions. Also, reactions compatible with chemical peritonitis have been reported. Over the period of a few months
Introduction
Icodextrin is a glucose polymer and a high molecular weight osmotic agent. Icodextrin is applied as an osmotic agent for peritoneal dialysis, essentially because it provides a sustained ultrafiltration over long dwell times [1] . This sustained osmotic effect relies on the large size of these molecules, which results in prolonged retention of osmotic agent in the peritoneal cavity and ultrafiltration in a colloid osmotic manner. Icodextrin dialysate probably produces this effect via intercellular pores, which in addition leads to increased transport and clearances of smaller proteins such as 2-microglobulin [2] . Icodextrin is also considered as an attractive approach to reduce the exposure of the patient and the peritoneal membrane to glucose [3] .
However, several side effects of icodextrin solutions have been described, including abdominal pain and, rarely allergic and hypersensitive reactions. Also, reactions suggesting chemical peritonitis have been reported. Several case studies described sterile peritonitis associated with the use of icodextrin solutions in CAPD patients [4] [5] [6] .
Between January 2002 and May 2002, a remarkable increase in the number of CAPD patients using icodextrin dialysate were diagnosed with sterile peritonitis in our unit. Five of those patients were included in a follow-up study evaluating the total leucocyte count, the leucocyte differentiation and the expression of CD14 on the peritoneal macrophage and peripheral monocyte populations. CD14 is a differentiation antigen and a receptor for lipopolysaccharide (LPS) and peptidoglycan (PGN) [7, 8] . LPS and PGN are known to upregulate their own receptor [9, 10] . CD14 plays a role in the transduction of activation signals for the production of cytokines. In this context, CD14 plays an important role in the innate immune response towards infective agents and could be an interesting marker to distinguish between bacterial or bacterial-like and sterile peritonitis.
This report describes the characteristics of sterile peritonitis caused by icodextrin solutions used in peritoneal dialysis.
Subjects and methods

Subjects
The Renal Division, University Hospital of Ghent, Belgium has currently 50 continuous ambulatory peritoneal dialysis (CAPD) patients under treatment; 26 patients of this population are treated with icodextrin dialysate (EXTRANEAL TM , Baxter SA, Lessines, Belgium) during an overnight dwell. From January 2002 to May 2002 an increased prevalence (total number, n ¼ 8) of episodes of sterile peritonitis among the patients treated with icodextrin dialysate was observed. Five of the latter patients are included in this report (two males and three females, mean age 68 ± 11 years). The patients had been exposed to icodextrin dialysate for 27 ± 16 months (range: 1-41 months). Sterile peritonitis was diagnosed if peritoneal leucocyte (>100/mm 3 ) counts were elevated and bacteriological cultures remained negative.
At the time the patients presented with signs of peritonitis [day 0 (d0)] the peritoneal effluent and a blood sample were collected. A routine peritoneal leucocyte count was obtained using a Coulter counter (Analis, Ghent, Belgium) and the peritoneal leucocyte population was differentiated based on forward and side scatter and fluorescence properties using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). In addition, CD14 expression on peritoneal macrophages and peripheral monocytes was analysed. The above-mentioned parameters were then further followed for 71 ± 21 days (range: 36-87 days) at variable time points, on the occasion of an ambulatory consultation. The follow-up time includes periods of interruption of icodextrin dialysate treatment for 44.4 ± 6.2 days (range: 36-51 days), as well as rechallenge episodes with icodextrin dialysate after presumed recovery of the peritonitis.
In parallel, the results of this population were compared on day 2 (d2), days 4-8 (d4-8) 
Statistical analysis
Data are presented as means ± SD. A paired Wilcoxon or unpaired Mann-Whitney test was used and statistical significance was accepted with P-values <0.05.
Results
Leucocyte count
On the day the patient presented with signs of peritonitis, the peritoneal leucocyte count in the group subsequently diagnosed with sterile peritonitis exceeded 100 leucocytes/mm 3 , with a mean value of 1358 ± 1006 leucocytes/mm 3 (range: 130-2900 leucocytes/mm 3 ). The patients with bacterial peritonitis had a mean peritoneal leucocyte count of 1512 ± 1004 leucocytes/mm 3 (range: 400-2900 leucocytes/mm 3 ) (P ¼ NS). The responsible micro-organisms were identified as: two Gram-negative (Bacteroides fragilis and Enterobacter cloacae) and four Gram-positive (three Staphylococcus aureus and one Streptococcus viridans) strains. Figure 1A illustrates that in the case of sterile peritonitis, the peritoneal leucocyte count did not significantly decrease before icodextrin dialysate administration was interrupted (within a mean of 6 ± 5 days after presentation; range: 2-14 days). In contrast, in bacterial peritonitis, the leucocyte count decreased below 100 leucocytes/mm 3 within 2 days after the start of antibiotic treatment [day 0: 1512 ± 1004 vs day 2: 88 ± 102 leucocytes/mm 3 In sterile peritonitis, after interruption of the treatment with icodextrin dialysate, and in accordance with the start of antibiotic treatment in the case of bacterial peritonitis, the leucocyte count decreased significantly from 574 ± 518 to 114 ± 123 leucocytes/mm 3 within 4-8 days (P < 0.05). However, the mean count remained still in excess of 100 leucocytes/mm 3 (P ¼ 0.0625 vs antibiotic treatment in bacterial peritonitis after the same interval).
On the other hand, a significant increase in the peritoneal leucocyte count was again observed (224 ± 99 vs 54 ± 30 leucocytes/mm 3 ; P < 0.05) on the day of the first check-up [within 7 days (range: 3-11 days)] after the restart of the treatment with icodextrin dialysate.
Peritoneal cell differentiation
Peritoneal macrophage population. In the case of sterile peritonitis in the patients on icodextrin dialysate, the differentiation of the peritoneal leucocyte population on the day of presentation (d0), revealed an excess of peritoneal macrophages of 18.3 ± 12.9% (range: 6.2-38.7%) compared to 4.0 ± 2.5% (range: 1.1-8.0%; P < 0.05) in the case of bacterial peritonitis. Figure 2 illustrates that during the follow-up period, no further significant difference in the percentage of peritoneal macrophages between sterile and bacterial peritonitis was observed.
In the case of sterile peritonitis, the percentage of peritoneal macrophages only significantly decreased and normalized after interruption of the treatment with icodextrin dialysate, from 15.9 ± 4.3 to 8.8 ± 4.5% (P ¼ 0.05) (Figure 2A ). In contrast, in the case of bacterial peritonitis, a significant increase in the percentage of peritoneal macrophages after the start of antibiotic treatment from 4.0 ± 2.5 to 10.2 ± 7.3% (P < 0.05) was observed ( Figure 2B ).
After the restart of the icodextrin dialysate treatment, on the day of the first consultation, an excess of peritoneal macrophages (18.9 ± 9.8%) was again observed. Fig. 2 . Follow-up of the percentage of peritoneal macrophages from CAPD patients diagnosed with sterile peritonitis associated with icodextrin dialysate (ico) (A) and from CAPD patients diagnosed with bacterial peritonitis (B). d0, day of presentation; d2, after 2 days; d4-8, after 4-8 days; dþ, further on. *P ¼ 0.05 vs before therapeutic intervention; P ¼ 0.0625 vs before rechallenge; @P < 0.05 vs CAPD patients diagnosed with sterile peritonitis. Fig. 1 . Follow-up of the peritoneal leucocyte count from CAPD patients diagnosed with sterile peritonitis associated with icodextrin dialysate (ico) (A) and from CAPD patients diagnosed with bacterial peritonitis (B). d0, day of presentation; d2, after 2 days; d4-8, after 4-8 days; dþ, further on. The dotted line marks the limit of 100 leucocytes/mm 3 . *P < 0.05 vs before therapeutic intervention; P < 0.05 vs before rechallenge; @P ¼ 0.0625 vs CAPD patients diagnosed with sterile peritonitis. During the follow-up period, a longer and more sustained percentage elevation of peritoneal granulocytes was observed before and even after interruption of the icodextrin dialysate, which is in contrast with a steady decrease of the percentage of peritoneal granulocytes in the case of bacterial peritonitis [from 88.6 ± 7.4 to 44.4 ± 24.9% on day 2 (P ¼ 0.062), and to 16.2 ± 17.9% (P < 0.01) on days 4-8] (Figure 3A and B).
Peritoneal eosinophil population. No significant increase in the eosinophil population was observed (data not shown).
CD14 expression on peritoneal and peripheral macrophages. CD14 expression on peritoneal macrophages is elevated compared to peripheral monocytes independently of the presence of peritonitis.
On the day the patients presented with signs of peritonitis (d0: sterile and bacterial), no significant increase in the expression of CD14 on peritoneal macrophages was observed compared to peritonitisfree CAPD patients.
In contrast, although in the case of bacterial peritonitis a significant increase in CD14 expression on peripheral blood monocytes was observed on d0, we could not find a significant effect of sterile peritonitis on the expression of this parameter compared to the CD14 expression on peripheral blood monocytes of peritonitis-free CAPD patients (Figure 4) .
During the follow-up period, no change in expression of CD14 could be observed on peritoneal macrophages in the case of the sterile peritonitis associated with icodextrin dialysate, even after a rechallenge with icodextrin dialysate and this in contrast to an increased expression of CD14 on peritoneal macrophages during bacterial peritonitis with a maximum 2 days after the start of treatment from 1992 ± 1239 to 3670 ± 2331 MFI (P < 0.05) ( Figure 5A and B).
Discussion
Over a short time period, a remarkable increase in the number of CAPD patients using icodextrin dialysate was diagnosed with sterile peritonitis in our unit. Icodextrin is applied in CAPD patients with ultrafiltration problems because of its associated advantage of a sustained ultrafiltration over a long dwell time.
Five of the eight CAPD patients diagnosed with sterile peritonitis were included in a follow-up study analysing peritoneal leucocyte count and differentiation in addition to the expression of CD14 on peritoneal macrophages and peripheral monocytes. The elevated peritoneal leucocyte count only significantly decreased after withdrawal of the treatment with icodextrin dialysate, which was presumed after Fig. 3 . Follow-up of the percentage of peritoneal granulocytes from CAPD patients diagnosed with sterile peritonitis associated with icodextrin dialysate (ico) (A) and from CAPD patients diagnosed with bacterial peritonitis (B). d0, day of presentation; d2, after 2 days; d4-8, after 4-8 days; dþ, further on. *P ¼ 0.05 and **P ¼ 0.062 vs before therapeutic intervention; P < 0.05 vs before rechallenge; &P < 0.05 vs d2; @P < 0.05 vs CAPD patients diagnosed with sterile peritonitis. Fig. 4 . CD14 expression on peripheral blood monocytes from peritonitis-free CAPD patients (A), CAPD patients diagnosed with bacterial peritonitis (B) and CAPD patients diagnosed with sterile peritonitis associated with icodextrin dialysate (C), on the day of presentation (d0). *P < 0.01 vs (A).
receiving the negative culture results ( Figure 1A ). In addition, when recovery was presumed and the treatment with icodextrin dialysate was restarted, this resulted again in an increase of the peritoneal leucocyte count.
In contrast to bacterial peritonitis, which is associated with a high polymorphonuclear leucocyte count and a low macrophage percentage, the sterile, cloudy icodextrin effluents were characterized by an excess of macrophages on the day of presentation (Figure 2 ). In addition, interruption of the icodextrin dialysate treatment was followed by a normalization of the percentage of peritoneal macrophages, but rechallenge again caused a rise in the percentage of peritoneal macrophages (Figure 2A) . In this context, the excess of macrophages in the peritoneal effluent at the day of presentation of the patient with clinical peritonitis, could be considered as a useful and early indicator of sterile peritonitis associated with icodextrin dialysate.
Macrophages are responsible for the release of substantial amounts of cytokines into the peritoneal fluid, leading to a profound intraperitoneal inflammatory status; this could have a negative impact on the peritoneal ultrafiltration and clearance capacity even in the absence of bacterial infection. These negative consequences especially occur if exposure to the cause of inflammation is prolonged, e.g. when sterile peritonitis is not expected. In addition, leucocyte counts remained slightly more elevated with an average in excess of 100 cells/mm 3 , even several days after withdrawal of icodextrin dialysate ( Figure 1A) .
The rapid appearance of macrophages into the peritoneum could point in the direction of the presence of a macrophage chemotactic agent in several batches of the fresh icodextrin solution. Our results indicate that, on the day of presentation of the CAPD patient with an elevated peritoneal leucocyte count (>100/mm 3 ), a peritoneal macrophage population exceeding 10%, together with an elevated percentage of peritoneal granulocytes is highly suggestive of a sterile peritonitis associated with icodextrin dialysate.
No significant increase in the eosinophil population was observed, suggesting that an allergic reaction is highly unlikely.
Our results confirm the data described in a few isolated case studies in which a sterile peritonitis associated with the use of icodextrin dialysate was characterized by an increase in peritoneal leucocyte count and an excess of macrophages. Likewise, a normalization of the leucocyte count after withdrawal of the icodextrin dialysate and an often immediate increase after re-exposure [4] [5] [6] were observed. To our knowledge, our study is the first to analyse several patients at a time, and to compare this with patients suffering from bacterial peritonitis. This study also offers a more in-depth kinetic analysis of the evolution over time.
In addition, the differentiation antigen CD14, a receptor for LPS and PGN, was evaluated during the follow-up period ( Figure 5 ). Several studies indicate that LPS influences the expression of CD14 [10] [11] [12] , and there is at least one study where an increase in CD14 expression is reported for PGN [12] . Our finding that CD14 expression is significantly enhanced in the presence of a bacterial peritonitis caused by Gram-negative as well as by Gram-positive bacteria, also points in this direction. PGN is shed by Grampositive bacteria; in contrast, LPS is released by Gram-negative bacteria.
In the case of bacterial peritonitis, we observed a significant increase in CD14 expression on peripheral blood monocytes on the day of presentation, compared to peripheral blood monocytes from peritonitis-free CAPD patients. In contrast, no change in CD14 expression on peripheral blood monocytes from patients diagnosed with sterile peritonitis was found (Figure 4) . CD14 expression on peritoneal macrophages from CAPD patients with bacterial and with sterile peritonitis, on the other hand, was not increased on the day of presentation compared to peritoneal Fig. 5 . Follow-up of the CD14 expression on peritoneal macrophages from CAPD patients diagnosed with sterile peritonitis associated with icodextrin dialysate (ico) (A) and from CAPD patients diagnosed with bacterial peritonitis (B). d0, day of presentation; d2, after 2 days; d4-8 after 4-8 days; dþ, further on. *P < 0.05 vs before therapeutic intervention; &P < 0.05 vs d2; @P < 0.05 vs CAPD patients diagnosed with sterile peritonitis.
macrophages from CAPD patients without peritonitis. During the follow-up period, however, bacterial peritonitis caused an increase in CD14 expression on peritoneal macrophages with a maximum on day 2 after the start of treatment, whereas no changes were observed in the case of sterile peritonitis associated with icodextrin dialysate ( Figure 5 ). Hence, sterile peritonitis is not likely to be caused by LPS or a LPSlike contamination.
There has been some recent suggestion that the sterile peritonitis in CAPD patients using icodextrin solutions is caused by a PGN contamination (>150 ng/ml) (Baxter S.A./N.V., personal communication), as this group of compounds was detected in several specific batches related to sterile peritonitis. This suggestion does not fit with our findings of CD14 expression, since both LPS and PGN have been shown to upregulate CD14 expression; therefore, we recommend that causative factors other than PGNs be investigated. Alternatively, specific PGN fractions without CD14-inducing capacity might be at play.
However, an almost immediate increase in peritoneal leucocyte count and percentage of peritoneal macrophages after restarting the icodextrin dialysate treatment was observed using batches which were assured to contain a PGN concentration below 20 ng/ml. In some cases a permanent withdrawal from icodextrin dialysate treatment was necessary. This also adds to the suggestion of a responsible factor other than 'contaminated' icodextrin solutions.
In conclusion, some batches of icodextrin solution used for CAPD contain a macrophage chemotactic agent that, despite the absence of bacterial infection, causes a sustained inflammatory state in the peritoneal cavity. Because no increase in the expression of the LPS receptor CD14 could be observed, the increased peritoneal leucocyte count is probably caused by factors other than LPS, PGN or LPS/PGN-like contamination.
